All
PODCAST: Expert insights in managing vitiligo, part 2 on dyspigmentation
April 1st 2015Two of the most vexing skin conditions that dermatologists manage are melasma and vitiligo. In one condition, too much pigmentation is present because of genetic, hormonal and environmental factors. In the other, there is a lack of melanin in the skin, presumably on an autoimmune basis. In part two of this discussion on dyspigmentation conditions, Seemal Desai, M.D., who is a board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options for vitiligo with Dermatology Times editorial advisor, Dr. Norman Levine.
Dinutuximab wins FDA approval for neuroblastoma
March 31st 2015FDA has approved dinutuximab (Unituxin, United Therapeutics) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk pediatric neuroblastoma patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
"Addiction" may fuel tanning, risk-taking
March 30th 2015Maui – Taken together, two new studies suggest that among teens, indoor tanning is linked with other risky behaviors, and that tanners may be seeking a sort of natural high. This information may help dermatologists discuss healthy living in general with patients.
Purse-String Suture vs. Second Intention Healing
March 26th 2015A team of dermatologists tried to determine whether purse-string sutures improve cosmetic outcome, healing time, and scarring, when compared with second-intention healing for circular defects on the trunk and extremities. Get results from their findings
Practice management tips for aesthetic offices
March 25th 2015Social media, an up-to-date web site, and a regular email newsletter highlighting what is new in your practice are ways to market yourself and your practice. Experts at the 2015 AAD also advise developing relationships with plastic surgery peers and carrying products for purchase at the office.
Team-based approach incorporates non-physician clinicians
March 25th 2015While non-physician clinicians cannot replace dermatologists, the role they play in dermatology practices is growing. However, there are key factors to consider, one expert says, including team structure, supervision and training.
Key to preventing medical errors includes keeping an open mind
March 24th 2015Dermatologists should refrain from developing an initial clinical impression and consider alternative diagnoses when seeing patients, an expert tells colleagues at the 73rd annual meeting of the American Academy of Dermatology.
Dermatologists should recognize BDD
March 23rd 2015While BDD is present in 2.4% of the general population, it can range from 9 - 14% in dermatology clinics. There are red flags that dermatologists can watch for, and depending on the severity, dermatologists may consider referring patients to mental health professionals.
Expert insights in managing melasma and vitiligo
March 20th 2015Two of the most vexing skin conditions dermatologists manage are melasma and vitiligo. Seemal Desai, M.D., board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options.
Advances in understanding, treating MCC
March 19th 2015Outcomes for patients with Merkel Cell Carcinoma are typically poor and therapeutic options are limited, but advances in understanding the biology of the disease, as well as emerging cutting-edge treatments are expected to improve the outlook, experts say.
Ipilimumab evaluated as adjuvant therapy
March 18th 2015Ipilimumab has been evaluated in the adjuvant setting. One expert predicts that ipilimumab’s positive effect on progression-free survival will translate into improvements in overall survival; however, he cautions that there is a risk:benefit ratio to be weighed.
Rosacea: Newer topical therapies are effective and well-tolerated
March 16th 2015Emerging therapies for rosacea have a favorable side effect profile and address specific symptoms of the condition; brimonidine, for example, addresses background erythema while ivermectin addresses the papules and pustules.